Note 3 - Merger with Old Cytocom (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Schedule of Business Acquisitions, by Acquisition [Table Text Block]

	July 27, 2021
Number of shares of the combined company owned by Cleveland BioLabs, Inc. stockholders		15,478,945	(1	)
Multiplied by the price per share of Cleveland BioLabs, Inc. common stock	$	4.99	(2	)
Total purchase price	$	77,239,936

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

	July 27, 2021
Tangible Assets Acquired
Cash and cash equivalents	$	13,116,460
Other receivables		25,142
Other current assets		44,507
Fixed assets - net		4,954
Panacela (67.57% ownership)		178,388
Total Tangible Assets		13,369,451
Assumed Liabilities
Accounts payable		(426,570	)
Accrued expenses		(41,755	)
Total Liabilities		(468,325	)
Net Tangible Assets/Liabilities		12,901,126
Intangible Assets Acquired
In-process R&D		-
Total Intangible Assets Acquired		-
Goodwill		64,338,810
Total Net Assets Acquired	$	77,239,936

Business Acquisition, Pro Forma Information [Table Text Block]

	Nine Months Ended September 30,
	2020			2021
Revenue	$	2,214,344		$	1,665,992
Net loss	$	(9,501,191	)	$	(24,612,658	)